Type i interferons as biomarkers in autoimmune diseases

Biomarkers in Medicine

Volumn 6, Issue 2, 2012, Pages 137-140

  Kalliolias, George D ^a,b   Kirou, Kyriakos A ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

autoimmunity; biomarkers; connective tissue disease; rheumatoid arthritis; systemic lupus erythematosus; type I IFN

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BIOLOGICAL MARKER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LA ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; RO ANTIBODY; SM ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; GENE EXPRESSION PROFILING; HUMAN; MYOSITIS; PLASMACYTOID DENDRITIC CELL; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; INTERFERON TYPE I;

EID: 84859060077     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.8     Document Type: Review

References (19)

1. Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res. Ther. 12(Suppl. 1), S1 (2010).
2. Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin. Immunol. 23(2), 113-121 (2011).
3. Denny MF, Thacker S, Mehta H et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110(8), 2907-2915 (2007).
4. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52(5), 1491-1503 (2005).
5. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 58(1), 251-262 (2008).
6. Nzeusseu Toukap A, Galant C, Theate I et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 56(5), 1579-1588 (2007).
7. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197(6), 711-723 (2003).
8. Bauer JW, Petri M, Batliwalla FM et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 60(10), 3098-3107 (2009).
9. Higgs BW, Liu Z, White B et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70(11), 2029-2036 (2011).
10. Merrill JT, Wallace DJ, Petri M et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a Phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 70(11), 1905-1913 (2011).
11. Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 62(2), 580-588 (2010).
12. Van Der Pouw Kraan TC, Wijbrandts CA, Van Baarsen LG et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 66(8), 1008-1014 (2007).
13. Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 62(2), 392-401 (2010).
14. Thurlings RM, Boumans M, Tekstra J et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 62(12), 3607-3614 (2010).
15. Van Baarsen LG, Wijbrandts CA, Rustenburg F et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res. Ther. 12(1), R11 (2010).
16. Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res. Ther. 12(Suppl. 1), S5 (2010).
17. Tak PP. IFN-beta in rheumatoid arthritis. Front. Biosci. 9, 3242-3247 (2004).
18. Van Holten J, Pavelka K, Vencovsky J et al. A multicentre, randomised, double blind, placebo controlled Phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64(1), 64-69 (2005).
19. Van Der Pouw Kraan TC, Van Gaalen FA, Kasperkovitz PV et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 48(8), 2132-2145 (2003)